hydroxychloroquine has been researched along with Proteinuria in 23 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present meta-analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria." | 9.12 | Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis. ( Feng, J; Li, H; Lu, X; Wang, S; Zhang, J, 2021) |
| "To compare the clinical efficacy, effect on serum C-reactive protein (CRP), serum amyloid A (SAA), and plasma interleukin-6 (IL-6) levels, and safety of tenidap with a combination of hydroxychloroquine-plus-piroxicam, and piroxicam alone, in the treatment of rheumatoid arthritis (RA) patients." | 9.08 | Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. ( Blackburn, WD; Caldwell, JR; Collins, RL; Fleischmann, R; Kaplan, H; Miller, MJ; Poiley, JE; Prupas, HM; Sikes, DH; Silverfield, JC, 1995) |
| "Hydroxychloroquine could be an option for patients with membranous nephropathy seeking to achieve proteinuria reduction and anti-PLA2R antibody reduction in addition to optimized RAASi." | 8.12 | Effects of hydroxychloroquine on proteinuria in membranous nephropathy. ( Cheng, XY; Cheng, YJ; Cui, Z; Liu, G; Meng, LQ; Wang, F; Wang, X; Zhang, YM; Zhao, MH, 2022) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 8.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| " This study aimed to estimate the rate of false positive proteinuria with the dipstick in patients with systemic lupus erythematosus (SLE) taking hydroxychloroquine." | 7.81 | Confirmed False Positive Proteinuria in Patients with Systemic Lupus Erythematosus Taking Hydroxychloroquine: a Spot Sample Measurement. ( Huang, WC; Lee, CH; Li, JY; Wang, JM; Wen, CY; Wu, MF; Yang, CY, 2015) |
| "To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients." | 7.75 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. ( Alarcón, GS; Bastian, HM; Danila, MI; McGwin, G; Pons-Estel, GJ; Reveille, JD; Vilá, LM; Zhang, J, 2009) |
| "Hydroxychloroquine (HCQ) is a well-known immunomodulator that is useful as in the treatment for lupus because of its inhibitory effect on toll-like receptors and cytokines, which are speculated to play a role in the pathogenesis of Immunoglobulin A (IgA) nephropathy (IgAN)." | 5.48 | Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, JW; Yang, YZ; Zhang, H, 2018) |
| "Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-α,IL-6 and TNF-α." | 5.46 | Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. ( Gao, R; Li, X; Wen, Y; Wu, W, 2017) |
| "The present meta-analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria." | 5.12 | Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis. ( Feng, J; Li, H; Lu, X; Wang, S; Zhang, J, 2021) |
| "To compare the clinical efficacy, effect on serum C-reactive protein (CRP), serum amyloid A (SAA), and plasma interleukin-6 (IL-6) levels, and safety of tenidap with a combination of hydroxychloroquine-plus-piroxicam, and piroxicam alone, in the treatment of rheumatoid arthritis (RA) patients." | 5.08 | Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. ( Blackburn, WD; Caldwell, JR; Collins, RL; Fleischmann, R; Kaplan, H; Miller, MJ; Poiley, JE; Prupas, HM; Sikes, DH; Silverfield, JC, 1995) |
| "Hydroxychloroquine (HCQ) is recommended as a treatment for IgA nephropathy (IgAN) to control proteinuria." | 4.31 | Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study. ( Liu, LJ; Lv, JC; Shi, SF; Si, FL; Tang, C; Zhang, H; Zhou, XJ, 2023) |
| "Hydroxychloroquine could be an option for patients with membranous nephropathy seeking to achieve proteinuria reduction and anti-PLA2R antibody reduction in addition to optimized RAASi." | 4.12 | Effects of hydroxychloroquine on proteinuria in membranous nephropathy. ( Cheng, XY; Cheng, YJ; Cui, Z; Liu, G; Meng, LQ; Wang, F; Wang, X; Zhang, YM; Zhao, MH, 2022) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 4.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| " The patient received induction therapy with steroids, cyclophosphamide and hydroxychloroquine followed by rapid clinical improvement and remission of proteinuria." | 3.96 | A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis. ( Boletis, JN; Liapis, G; Marinaki, S; Skalioti, C; Vallianou, K, 2020) |
| " This study aimed to estimate the rate of false positive proteinuria with the dipstick in patients with systemic lupus erythematosus (SLE) taking hydroxychloroquine." | 3.81 | Confirmed False Positive Proteinuria in Patients with Systemic Lupus Erythematosus Taking Hydroxychloroquine: a Spot Sample Measurement. ( Huang, WC; Lee, CH; Li, JY; Wang, JM; Wen, CY; Wu, MF; Yang, CY, 2015) |
| "To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients." | 3.75 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. ( Alarcón, GS; Bastian, HM; Danila, MI; McGwin, G; Pons-Estel, GJ; Reveille, JD; Vilá, LM; Zhang, J, 2009) |
| "Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients." | 2.72 | Hydroxychloroquine in IgA nephropathy: a systematic review. ( Mircescu, G; Stefan, G, 2021) |
| "Acute acalculous cholecystitis (AAC) is an extremely rare manifestation of systemic lupus erythematous (SLE)." | 2.72 | Acute acalculous cholecystitis as the initial manifestation of systemic lupus erythematous: A case report. ( Kim, Y; Lee, J; Lee, YJ, 2021) |
| "Proteinuria is one of the most typical manifestations of kidney involvement in Systemic Lupus Erythematosus (SLE)." | 1.62 | "Protenuria in SLE: Is it always lupus?" ( Alessandri, C; Celia, AI; Cerbelli, B; Conti, F; d'Amati, G; Diomedi-Camassei, F; Leuzzi, V; Priori, R; Scrivo, R, 2021) |
| "Hydroxychloroquine (HCQ) is a well-known immunomodulator that was recently used in immunoglobulin A (IgA) nephropathy (IgAN) due to its antiproteinuric effects." | 1.56 | Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Tang, C; Zhang, H, 2020) |
| "Hydroxychloroquine (HCQ) is a well-known immunomodulator that is useful as in the treatment for lupus because of its inhibitory effect on toll-like receptors and cytokines, which are speculated to play a role in the pathogenesis of Immunoglobulin A (IgA) nephropathy (IgAN)." | 1.48 | Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, JW; Yang, YZ; Zhang, H, 2018) |
| "Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-α,IL-6 and TNF-α." | 1.46 | Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. ( Gao, R; Li, X; Wen, Y; Wu, W, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 11 (47.83) | 2.80 |
| Authors | Studies |
|---|---|
| Stefan, G | 1 |
| Mircescu, G | 1 |
| Cheng, YJ | 1 |
| Cheng, XY | 1 |
| Zhang, YM | 1 |
| Wang, F | 1 |
| Wang, X | 1 |
| Meng, LQ | 1 |
| Liu, G | 1 |
| Cui, Z | 1 |
| Zhao, MH | 1 |
| Zhang, J | 2 |
| Lu, X | 1 |
| Feng, J | 1 |
| Li, H | 1 |
| Wang, S | 1 |
| Choi, M | 1 |
| Hwang, JR | 1 |
| Sung, JH | 1 |
| Byun, N | 1 |
| Seok, YS | 1 |
| Cho, GJ | 1 |
| Choi, SJ | 1 |
| Kim, JS | 1 |
| Oh, SY | 1 |
| Roh, CR | 1 |
| Si, FL | 1 |
| Tang, C | 2 |
| Lv, JC | 5 |
| Shi, SF | 5 |
| Zhou, XJ | 1 |
| Liu, LJ | 5 |
| Zhang, H | 5 |
| Fanouriakis, A | 1 |
| Kostopoulou, M | 1 |
| Cheema, K | 1 |
| Anders, HJ | 1 |
| Aringer, M | 1 |
| Bajema, I | 1 |
| Boletis, J | 1 |
| Frangou, E | 1 |
| Houssiau, FA | 1 |
| Hollis, J | 1 |
| Karras, A | 1 |
| Marchiori, F | 1 |
| Marks, SD | 1 |
| Moroni, G | 1 |
| Mosca, M | 1 |
| Parodis, I | 1 |
| Praga, M | 1 |
| Schneider, M | 1 |
| Smolen, JS | 1 |
| Tesar, V | 1 |
| Trachana, M | 1 |
| van Vollenhoven, RF | 1 |
| Voskuyl, AE | 1 |
| Teng, YKO | 1 |
| van Leew, B | 1 |
| Bertsias, G | 1 |
| Jayne, D | 1 |
| Boumpas, DT | 1 |
| Vallianou, K | 1 |
| Skalioti, C | 1 |
| Liapis, G | 1 |
| Boletis, JN | 1 |
| Marinaki, S | 1 |
| Chen, YQ | 4 |
| Fayed, A | 1 |
| El Menyawi, MM | 1 |
| Ghanema, M | 1 |
| Shaker, O | 1 |
| Elgohary, R | 1 |
| Celia, AI | 1 |
| Priori, R | 1 |
| Cerbelli, B | 1 |
| Diomedi-Camassei, F | 1 |
| Leuzzi, V | 1 |
| Scrivo, R | 1 |
| Alessandri, C | 1 |
| d'Amati, G | 1 |
| Conti, F | 1 |
| Lee, J | 1 |
| Lee, YJ | 1 |
| Kim, Y | 1 |
| Gao, R | 1 |
| Wu, W | 1 |
| Wen, Y | 1 |
| Li, X | 1 |
| Yang, YZ | 3 |
| Wang, JW | 1 |
| Bao, YF | 1 |
| Yang, C | 1 |
| Zhu, SN | 1 |
| Sui, GL | 1 |
| Floege, J | 1 |
| Chen, P | 1 |
| Cai, QQ | 1 |
| Fangtham, M | 1 |
| Petri, M | 2 |
| Wang, JM | 1 |
| Li, JY | 1 |
| Huang, WC | 1 |
| Wen, CY | 1 |
| Lee, CH | 1 |
| Yang, CY | 1 |
| Wu, MF | 1 |
| Pons-Estel, GJ | 1 |
| Alarcón, GS | 1 |
| McGwin, G | 1 |
| Danila, MI | 1 |
| Bastian, HM | 1 |
| Reveille, JD | 1 |
| Vilá, LM | 1 |
| Zheng, ZH | 1 |
| Zhang, LJ | 1 |
| Liu, WX | 1 |
| Lei, YS | 1 |
| Xing, GL | 1 |
| Zhang, JJ | 1 |
| Quan, SX | 1 |
| Liu, D | 1 |
| Hu, DS | 1 |
| Li, LL | 1 |
| Liu, ZS | 1 |
| Kasitanon, N | 1 |
| Fine, DM | 1 |
| Haas, M | 1 |
| Magder, LS | 1 |
| Blackburn, WD | 1 |
| Prupas, HM | 1 |
| Silverfield, JC | 1 |
| Poiley, JE | 1 |
| Caldwell, JR | 1 |
| Collins, RL | 1 |
| Miller, MJ | 1 |
| Sikes, DH | 1 |
| Kaplan, H | 1 |
| Fleischmann, R | 1 |
| Rockhold, L | 1 |
| Harisdangkul, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| [NCT02942381] | Phase 2 | 60 participants (Actual) | Interventional | 2016-09-13 | Completed | ||
| Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)[NCT04937907] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-09-08 | Recruiting | ||
| Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743] | 72 participants (Actual) | Interventional | 2018-04-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for hydroxychloroquine and Proteinuria
| Article | Year |
|---|---|
Hydroxychloroquine in IgA nephropathy: a systematic review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Glomerulonephritis, IGA; Humans; Hydroxychloroquine; Immun | 2021 |
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis.
Topics: Glomerulonephritis, IGA; Humans; Hydroxychloroquine; Immunoglobulin A; Proteinuria; Renin-Angiotensi | 2021 |
Acute acalculous cholecystitis as the initial manifestation of systemic lupus erythematous: A case report.
Topics: Acalculous Cholecystitis; Acute Disease; Adult; Aged; Antibodies, Antinuclear; Antirheumatic Agents; | 2021 |
2013 update: Hopkins lupus cohort.
Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc | 2013 |
2 trials available for hydroxychloroquine and Proteinuria
| Article | Year |
|---|---|
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Topics: Adult; Creatinine; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glo | 2019 |
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Topics: Adult; Creatinine; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glo | 2019 |
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Topics: Adult; Creatinine; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glo | 2019 |
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Topics: Adult; Creatinine; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glo | 2019 |
Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Antir | 1995 |
17 other studies available for hydroxychloroquine and Proteinuria
| Article | Year |
|---|---|
Effects of hydroxychloroquine on proteinuria in membranous nephropathy.
Topics: Autoantibodies; Female; Glomerulonephritis, Membranous; Humans; Hydroxychloroquine; Immunosuppressiv | 2022 |
Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model.
Topics: Animals; Blood Pressure; Endothelial Cells; Endothelin-1; Female; Hydroxychloroquine; Hypertension; | 2022 |
Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study.
Topics: Adrenal Cortex Hormones; Case-Control Studies; Follow-Up Studies; Glomerular Filtration Rate; Glomer | 2023 |
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Topics: Antirheumatic Agents; Azathioprine; Calcineurin Inhibitors; Drug Therapy, Combination; Europe; Glome | 2020 |
A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis.
Topics: Aged; Antirheumatic Agents; Arthritis; Chronic Urticaria; Complement System Proteins; Cyclophosphami | 2020 |
Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study.
Topics: Adrenal Cortex Hormones; Adult; Case-Control Studies; Drug Therapy, Combination; Female; Glomerulone | 2020 |
Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Biomarkers; Case-Control Studies; Complement | 2020 |
"Protenuria in SLE: Is it always lupus?"
Topics: Antirheumatic Agents; Biopsy; Diagnosis, Differential; Enzyme Replacement Therapy; Fabry Disease; Fe | 2021 |
Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antimalarials; Blood Pressure; Case-Control Studies; | 2017 |
Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Com | 2018 |
Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase?
Topics: Antimalarials; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Hydroxychloroquine; Prot | 2019 |
Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.
Topics: Adrenal Cortex Hormones; Adult; Case-Control Studies; Female; Glomerular Filtration Rate; Glomerulon | 2019 |
Confirmed False Positive Proteinuria in Patients with Systemic Lupus Erythematosus Taking Hydroxychloroquine: a Spot Sample Measurement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; False Positive Reactions; F | 2015 |
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.
Topics: Adult; Antirheumatic Agents; Black or African American; Cohort Studies; Disease Progression; Female; | 2009 |
Predictors of survival in Chinese patients with lupus nephritis.
Topics: Adolescent; Adult; Age of Onset; Aged; Asian People; Child; China; Cohort Studies; Creatinine; Femal | 2012 |
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Rheumatoid arthritis occurring with sickle cell anemia--treatment dilemma.
Topics: Anemia, Sickle Cell; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Lung Diseases; Middl | 1989 |